Salmon R J, Zafrani B, Labib A, Asselain B, Girodet J
Dis Colon Rectum. 1986 May;29(5):336-40. doi: 10.1007/BF02554126.
From 1968 to 1982, 195 patients with invasive cancer of the anal canal were treated (average age, 67 +/- 11 years; range, 38 to 85 years; sex ratio [women/men]: 5/1). Histology revealed: cloacogenic cancer, 20 cases; squamous cancer, poorly differentiated, 30; moderately differentiated, 68; well differentiated, 77. The initial size of the cloacogenic cancers was smaller than the squamous cancers. Invasion less than half the circumference of the canal was 90 and 74 percent, respectively. No patients with cloacogenic cancer presented with positive inguinal nodes; however, there were 22 unilateral and five bilateral positive nodes in the squamous cancers. All 195 patients received radiotherapy as the first treatment. There were no differences among the patients operated on with respect to sterilized operative specimens, postradiotherapy sequelae, perineal recurrences, and/or visceral metastases in the cloacogenic and squamous cancers. Five-year survival was better in cloacogenic (62 percent) than in squamous cancers (56 percent); this difference was not significant, and was related to the initial size of the tumor. The number of patients with no evidence of disease and good anal function was significantly related to the initial size of the tumor, and was independent of the histologic findings.
1968年至1982年期间，对195例肛管浸润癌患者进行了治疗（平均年龄67±11岁；范围38至85岁；性别比[女性/男性]：5/1）。组织学检查显示：泄殖腔源癌20例；低分化鳞癌30例；中分化鳞癌68例；高分化鳞癌77例。泄殖腔源癌的初始大小小于鳞癌。肛管浸润小于半周的比例分别为90%和74%。泄殖腔源癌患者无腹股沟淋巴结阳性；然而，鳞癌中有22例单侧和5例双侧淋巴结阳性。所有195例患者均接受放疗作为首选治疗。在接受手术的患者中，泄殖腔源癌和鳞癌在手术标本无菌、放疗后后遗症、会阴复发和/或内脏转移方面无差异。泄殖腔源癌的5年生存率（62%）高于鳞癌（56%）；这种差异不显著，且与肿瘤的初始大小有关。无疾病证据且肛门功能良好的患者数量与肿瘤的初始大小显著相关，且与组织学检查结果无关。
